SCHEMBL4941844

SCHEMBL4941844

COc1ccc(-c2nnc(O)n2-c2ccccc2F)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNN4 O15554 1/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41
RAB9A P51151 1/20 0.41
CRHR2 Q13324 1/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2E1 P05181 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4940573 0.90 HSP90AA1 (0.45) KDM4ELMNATSHRHSP90AA1MEN1
SCHEMBL4941855 0.87 PDE2A (0.42) KDM4ELMNAHSP90AA1MEN1KMT2A
SCHEMBL3310440 0.83 HSP90AA1 (0.42) KDM4EHSP90AA1MEN1KMT2AKCNN4
SCHEMBL4940524 0.79 FYN (0.44) MEN1KMT2AMAPTSMN1; SMN2NPC1
SCHEMBL3310378 0.78 KDM4E (0.43) KDM4ELMNATSHRKMT2AKCNN4
SCHEMBL13328107 0.77 HSP90AA1 (0.48) KDM4ELMNATSHRHSP90AA1KCNN4
SCHEMBL13472834 0.77 KCNN4 (0.36) KDM4EHSP90AA1KCNN4SMN1; SMN2ALDH1A1
SCHEMBL13328105 0.77 CYP1A1 (0.40) KDM4ELMNAKCNN4MAPTSMN1; SMN2
SCHEMBL4942213 0.77 CACNA2D1 (0.44) KDM4ELMNAMEN1KMT2ACYP1A1
SCHEMBL4948249 0.74 ABCC1 (0.46) KDM4ETSHRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US claimed
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 KDM4E 3777/4885LMNA 3962/4885TSHR 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.